Filter
185
Filtered Results: 185
Text search:
dolutegravir
Featured
Recommendations
22
New Publications
43
Language
Document type
No document type
87
Guidelines
43
Studies & Reports
34
Manuals
9
Strategic & Response Plan
5
Fact sheets
3
Infographics
2
Training Material
1
Situation Updates
1
Countries / Regions
Global
7
Argentina
7
South Africa
7
Malawi
5
Latin America and the Carribbean
5
Kenya
4
Brazil
4
Colombia
3
Africa
3
Namibia
3
Venezuela
2
South–East Asia Region
2
Botswana
2
Myanmar / Burma
2
Nepal
1
Thailand
1
Ukraine
1
Lesotho
1
Chile
1
Nigeria
1
Burkina Faso
1
Peru
1
Zimbabwe
1
Philippines
1
Guinea
1
Mozambique
1
Congo, Democratic Republic of
1
Western Pacific Region
1
Western and Central Europe
1
North America
1
Bolivia
1
Uganda
1
Central African Republic
1
Ethiopia
1
Chad
1
Zambia
1
Somalia
1
Authors & Publishers
Publication Years
Category
Policies & Guidelines HIV & TB
32
HIV & STI
18
TB
7
Drugs & Medical Equipment
5
COVID-19
4
Guidelines
4
Pediatrics
3
Humanitarian Crisis
3
Paediatrics
2
Women & Child Health
2
Studies & Reports
2
Statistics
2
Pharmacy & Technologies
2
Communicable Diseases
1
Hepatitis
1
Emergency Health Kits
1
Buruli Ulcer
1
Countries
1
Policies
1
Capacity Building
1
Other
1
Maternal Health
1
Primary Health Care
1
Neurology & Psychology
1
Reproductive Health
1
Toolboxes
Antiretroviral Treatment ART
28
Clinical Aspects, Treatment & Prevention
22
ART Drug Resistance
16
Treatment & Prevention
15
Treatment Guidelines HIV
14
General Reports
13
Children & Adolescents
13
Global
8
Reports & Studies
7
Prevention & Control
6
Universal Health Coverage UHC and 90-90-90 Strategy
6
Essential Medicines & Devices Lists
6
Reports & Studies Children HIV
6
Policies
5
Drug resistance
5
Clinical Aspects
4
Adults
4
Essential Medicines
4
General Aspects
4
Opportunistic Infections
3
HIV and COVID-19
3
Co-Morbidities (except TB)
3
Prevention of mother-to-child transmission (PMTCT)
3
TB/HIV Coinfection
3
HIV service delivery
3
Lobby and Advocacy
3
Eastern Europe and central Asia
3
HIV testing & services
2
Prevention Guidelines
2
International
2
Essential List
2
Country specific documents
2
Brazil
2
Rational use of Medicine
2
Argentina
2
Access to treatment and laboratory
2
Detection & Diagnosis
2
Postexposure Prophylaxis (PEP), Pre-Exposure Prophylaxis (PrEP)
2
Policies and guidelines
2
Depression
2
Eastern and Southern Africa
2
Drugs
1
Policies & Strategies
1
HIV support organizations
1
Childhood TB
1
Substance Use Disorders, Others
1
Schizophrenia
1
HIV
1
Others
1
Children
1
Health & Refugee
1
General
1
Laboratory
1
For General Public & Community
1
Global Impact: Socio-economic, health services, TB & HIV
1
Guidelines
1
Tips & Best Practice Examples
1
TB/HIV
1
Community Health Workers CHW
1
Colombia
1
Model Formulary
1
Mental Disorders
1
Situation Reports & Updates
1
General
1
Strategies & Roadmaps
1
Clinical Aspects & Diagnostics
1
West and central Africa
1
Health Worker
1
Drug resistant TB
1
Neurological Disorders
1
Substance Use Disorders & Addiction
1
Community Worker
1
Bipolar Affective Disorders
1
TB/HIV Global
1
Regions
1
Prophylactic Treatment
1
Training
1
HIV / AIDS
1
HIV and coinfection
1
Testing Guidelines
1
Epidemiology
1
Epidemiology
1
HIV in Key Populations
1
SEAR (South-east Asia Region)
1
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on
dolutegravir-based antiretroviral therapy (November 2020– September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 ...
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el
mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este
antirretrovírico en las poblaciones tratadas con esquemas que lo conti...
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi...
This technical report summarizes the discussions on the status of programmatic transition to tenofovir, lamivudine and dolutegravir (TLD) in low– and middle- income countries, addressing the best practices and major challenges faced by HIV programmes.
The latest data on safety and efficacy of do...
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
populations sous TAR. Bien que la résistance au DT...
Em meados de 2021, os programas nacionais de SIDA começaram a fazer a transição do tratamento para crianças que vivem com VIH dolutegravir (DTG) 10 mg sulcado, comprimidos dispersíveis, também conhecido como DTG pediátrico (pDTG). A rápida introdução e implementação do pDTG é uma priori...
WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-dolutegravir based regimens.
Results are used to inform A...
The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo...
July 2021. This publication brings together important clinical and programmatic updates produced by WHO since 2016 and provides comprehensive, evidence-informed recommendations and good practice statements within a public health, rights-based and person-centred approach.
These guidelines bring in...
Médecins sans Frontières access campaign
Issue Brief
Accessed: 28.11.2019
Version: 14 March 2019; A one-page reference guide to all the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions.
The previous edition of the drugs chart is also available to download in Russian.
htb supplement: 2018 Vol 19:(1)
New drugs in development
July 2018
www.i-Base.info
الأدوية الأساسية
recommended
. MSF Essential Drugs Guidelines دليل عملي موجه للأطباء والصيادلة والممرضين والمساعدين الطبيين
Accessed on 20.08.2022
Antirretrovirales de uso general
Antirretrovirales de uso en pacientes con múltiples fracasos terapéuticos
No antirretrovirales de uso general
No antirretrovirales de uso nominal
Medicación para tratamiento de tuberculosis p.línea
Medicación para tratamiento d...
Medicines and medical devices for 10 000 people for approximately three months
Developed by the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission—
A Working Group of the Office of AIDS Research Advisory Council (OARAC)
Accessed: 12.02.2020
www.i-Base.info
Accessed: 28.11.2019
Accessed: 19.10.2019
MSF provides treatment for HIV and tuberculosis (TB) in more than 20 countries around the world. The report Burden sharing or burden shifting? How the HIV/TB response is being derailed examines the situation in nine countries where MSF runs programmes: Central African Republic, Democratic Republic ...
